论文部分内容阅读
目的探讨罗格列酮治疗2型糖尿病对防治大血管病变的临床价值。方法按1999年WHO的诊断标准确诊的2型糖尿病患者65例,比较用药前后颈动脉内膜中层厚度及各代谢指标的变化。结果65例患者治疗后颈动脉内膜中层厚度较治疗前变薄,差异有统计学意义;治疗前后空腹血糖、餐后2h血糖、糖化血红蛋白、空腹胰岛素、餐后2h胰岛素、总胆固醇、甘油三酯比较,差异有统计学意义(P<0.01)。试验结束时无一例心衰及其他严重不良事件发生。结论罗格列酮能显著改善大血管病变的危险因素,延缓2型糖尿病大血管病变的进展。
Objective To investigate the clinical value of rosiglitazone in the prevention and treatment of type 2 diabetes mellitus. Methods Sixty-five patients with type 2 diabetes mellitus diagnosed according to the diagnostic criteria of WHO in 1999 were enrolled. The changes of carotid intima-media thickness and each metabolic index were compared before and after treatment. Results The carotid artery intima-media thickness became thinner after treatment in 65 patients, the difference was statistically significant. Before and after treatment, fasting blood glucose, postprandial 2h blood glucose, glycosylated hemoglobin, fasting insulin, 2h postprandial insulin, total cholesterol, Ester, the difference was statistically significant (P <0.01). No heart failure and other serious adverse events occurred at the end of the trial. Conclusion Rosiglitazone can significantly improve the risk factors of macrovascular disease and delay the progression of macrovascular disease in type 2 diabetes mellitus.